HC Wainwright Issues Positive Forecast for AVXL Earnings

Anavex Life Sciences Corp. (NASDAQ:AVXL) – Investment analysts at HC Wainwright boosted their Q1 2025 earnings per share (EPS) estimates for Anavex Life Sciences in a report released on Thursday, December 26th. HC Wainwright analyst R. Selvaraju now anticipates that the biotechnology company will post earnings per share of ($0.17) for the quarter, up from their prior forecast of ($0.19). HC Wainwright currently has a “Buy” rating and a $42.00 target price on the stock. The consensus estimate for Anavex Life Sciences’ current full-year earnings is ($0.55) per share. HC Wainwright also issued estimates for Anavex Life Sciences’ Q2 2025 earnings at ($0.18) EPS, Q3 2025 earnings at ($0.21) EPS and FY2025 earnings at ($0.73) EPS.

Separately, D. Boral Capital reiterated a “buy” rating and issued a $46.00 target price on shares of Anavex Life Sciences in a research note on Monday, December 23rd.

Anavex Life Sciences Trading Down 2.7 %

Shares of Anavex Life Sciences stock opened at $10.74 on Monday. The company’s 50-day moving average price is $8.40 and its 200-day moving average price is $6.51. The company has a market cap of $910.92 million, a price-to-earnings ratio of -21.48 and a beta of 0.73. Anavex Life Sciences has a 12-month low of $3.25 and a 12-month high of $14.44.

Anavex Life Sciences (NASDAQ:AVXL) last issued its earnings results on Monday, December 23rd. The biotechnology company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.03.

Institutional Trading of Anavex Life Sciences

Institutional investors and hedge funds have recently modified their holdings of the business. Orion Capital Management LLC grew its holdings in shares of Anavex Life Sciences by 666.7% during the third quarter. Orion Capital Management LLC now owns 11,500 shares of the biotechnology company’s stock worth $65,000 after purchasing an additional 10,000 shares in the last quarter. PVG Asset Management Corp bought a new stake in Anavex Life Sciences during the third quarter valued at approximately $74,000. Atria Investments Inc purchased a new position in Anavex Life Sciences in the 3rd quarter worth approximately $76,000. BNP Paribas Financial Markets grew its stake in Anavex Life Sciences by 97.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 15,074 shares of the biotechnology company’s stock worth $86,000 after buying an additional 7,421 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. increased its holdings in shares of Anavex Life Sciences by 64.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 16,309 shares of the biotechnology company’s stock worth $93,000 after buying an additional 6,366 shares during the last quarter. Hedge funds and other institutional investors own 31.55% of the company’s stock.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.